PDB15 COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN  by Marinel.lo, J et al.
A404 Paris Abstracts
from the budget of both payers would raise by 579.5 thousand PLN (130.3 thousand 
a) in 2009 and 1.2 mln PLN (261 thousand a) in 2010. Depending on parameter 
changes, the budget would change by o 17% and o19% for NHS and both payers 
perspective, respectively. CONCLUSIONS: The reimbursement of vildagliptin will 
cause the raise of NHF expenses by 0.37% in 2009 and 0.70% in 2010 of the budget 
spent for oral drugs reimbursed in diabetes mellitus. For both payers’ perspective, the 
reimbursement of vildagliptin will cause the raise expenses by 0.27% in 2009 and 
0.53% in 2010 of the budget.
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OBJECTIVES: To estimate the health care direct costs of an episode of extensive 
superﬁcial or deep uncomplicated foot ulcer of neuropathic origin in patients with 
diabetes in Spain and identify the key factors that inﬂuence total costs. METHODS: 
A retrospective observational study of patients with an episode of foot ulcer during 
the period from January 2007 through December 2008 in 10 Spanish centres was 
performed. Data about sociodemographic characteristics, duration of the episode and       
health care-related resources were considered. The following resources were collected      
from hospital records: inpatient hospitalisations, surgeries, outpatient visits (specialists 
and primary care physician), diagnostic procedures, laboratory tests, ulcer-related 
cures, antibiotics and orthotic devices. Unitary cost (a, year 2009 values) data were 
taken from a Spanish Database of Health Costs and the Catalogue of Medicinal 
Products. RESULTS: Ninety-two patients (29.3% with one or more previous ulcers) 
with a foot ulcer episode were identiﬁed. The majority of cases were males (76.9%).        
Patients’ mean age was 65.20 o 10.90 years and 50.0% of these were retired. Average      
duration of an ulcer episode was 131 o 123 days. Most prevalent comorbidities were 
arterial hypertension (62.0% of cases), diabetic retinopathy (41.3%), renal impair-
ment (30.4%), dyslipidemias (25.0%) and myocardial infarction (19.6%). Concomi-
tant infections during the episode were reported in 33.7% of patients. The average 
cost per patient and ulcer episode was a17,262 (95% conﬁdence interval [CI], 
a11,315, a23,715). The most important categories of costs were for surgeries (a7054, 
95%CI, a6043–a8200, 40.9% of costs), inpatient hospitalisations (a6197, 95%CI, 
a3605–a8878, 35.9% of total costs), and ulcer-related cures (a2864, 95%CI, a1127–
a4759, 16.6% of total costs). Among surgeries, the most relevant were debridements 
and amputations. CONCLUSIONS: An episode of a neuropathic extensive superﬁcial 
or deep uncomplicated diabetic foot ulcer generates a substantial economic burden, 
with a mean cost per patient of a17,262. Surgeries, hospitalisations and ulcer-related 
cures represent 93.4% of total costs.
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OBJECTIVES: Poor glycemic control is associated with increased morbidity and 
mortality among hospitalized patients. Insulin aspart may be more effective in achiev-
ing glycemic control than human insulin. This study compares glycemic control, length 
of stay (LOS), hospital mortality, and charges for hospitalized patients receiving 
insulin aspart or human bolus insulin. METHODS: This study is a retrospective 
analysis of the Health Facts® database (Cerner Corporation, Kansas City, MO). 
Health Facts is a unique database built from hospital comprehensive clinical records 
including pharmacy, laboratory, emergency room, admission, and billing information 
from hospitals throughout the United States, all time-stamped and sequenced. The 
sample included 36,991 medical patients with discharge dates from January 1, 2004 
through December 31, 2007. Patients were segmented into those who exclusively 
received insulin aspart (n  4605, 12.5%) or human (n  32386, 87.6%) bolus insulin. 
Outcomes of interest included blood glucose (BG) control (overall mean BG  140 mg/
dL), length of stay (LOS), in-patient mortality, and hospital charges (in $2007). 
Results were compared with t-tests or chi-square tests. RESULTS: Insulin aspart 
patients demonstrated better blood glucose control (34.22% vs. 30.78% with mean 
BG  140 mg/dL, p  0.001) even though they experienced increased illness as dem-
onstrated by higher Charlson comorbidity scores (2.0 (1.7) vs. 1.9 (1.8), p  0.001) 
and had more heart, kidney, and lung diseases diagnosed during their stay. Insulin 
aspart was also associated with shorter LOS (5.5 (5.4) vs. 6.3 (6.8) p  0.001), lower 
mortality (3.8% vs. 8.7%, p  0.001) and fewer total charges ($25,074 (28,775) vs. 
$33,472 (41704), p  0.001). CONCLUSIONS: Insulin aspart patients appeared to 
have better glycemic control, shorter LOS, lower mortality and reduced hospital 
charges than patients on human bolus insulin. Multivariate adjustments are needed 
to conﬁrm these ﬁndings but the unadjusted results suggest insulin aspart is associated 
with better outcomes than human bolus insulin.
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OBJECTIVES: To estimate treatment costs attributable to overweight or obese status 
in diabetic patients in the U.S.A. METHODS: The data was drawn from the 2003–
2006 Medical Expenditure Panel Survey. Adult patients (18–74 years-old) with dia-
betes were identiﬁed based on a self-reported diagnosis or ICD-9-CM code of 250. 
Patients with pregnancy, malignancy, kidney dialysis, immunodeﬁciency, or body-
mass-index (BMI) 18.5 were excluded. Medical treatment costs included ofﬁce based 
physician/outpatient visits, emergency room visits, or hospitalizations, excluding 
dental problems and injuries. The treatment costs attributable to being overweight 
(25 a BMI  30) or obese (BMI q 30) at various points of the cost distribution were 
estimated using weighted quantile regression after controlling for demographics, 
comorbidities, and other study variables. Treatment costs attributable to being over-
weight/obese were calculated by the differences in the actual treatment costs for over-
weight/obese patients and the expected costs if obese patients were normal-weight 
patients using the study variable coefﬁcients obtained from all patients. All costs were 
converted to 2006 U.S. dollars using price indices. Data were analyzed using SAS and 
SUDAAN. RESULTS: A total of 5338 patients with diabetes were selected for this 
study. Approximately 88% of the diabetic patients were overweight (31%) or obese 
(57%). Compared with normal-weight patients, the incremental treatment costs attrib-
utable to obesity were signiﬁcantly higher by $35, $96, $196, $290, and $739 at the 
10th, 25th, 50th, 75th, and 90th percentiles, respectively. Similar trends were found in 
overweight patients compared with those of normal-weight, but the attributable costs 
were not signiﬁcantly different except at the 75th percentile point. CONCLUSIONS: 
The overall economic burdens attributable to being overweight and obese in diabetic 
patients were substantial and increased signiﬁcantly in the upper tail of the treatment 
cost distribution. The important ﬁnding that the magnitude of attributable costs 
increased across the distribution of treatment costs would not have been possible 
without the quantile regression method.
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OBJECTIVES: The clinical effectiveness of exenatide and glargine is well established 
for the treatment of type 2 diabetes (T2D). However, the relative economic and utiliza-
tion impact of these therapies is uncertain. This study examined the cost offsets associ-
ated with the use of exenatide compared to glargine in patients with T2D. METHODS: 
A retrospective analysis was conducted using a large, managed care claims database. 
Adult patients with T2D who had initiated either exenatide (N  9264) or glargine 
(N  3791) therapy between April 1, 2005 and June 30, 2007 with pre- (6 months) 
and post-index (12 months) continuous eligibility were included. Annual mean total 
medical costs and several mean cost components were estimated using propensity score 
stratiﬁcation to control for baseline demographic, clinical and resource utilization 
variables. Mean costs were estimated using nonparametric bootstrapping. RESULTS: 
Exenatide-treated patients had signiﬁcantly lower total direct medical ($20,792 vs. 
$24,954, p  0.0001), inpatient ($4,836 vs. $6,966, p  0.0001), outpatient ($9,510 
vs. $11,858, p  0.0001), and emergency room (ER) costs ($96 vs. $131, p  0.04). 
Exenatide-treated patients had higher total prescription costs ($6349 vs. $6000, 
p  0.0004). Furthermore, exenatide-treated patients had signiﬁcantly lower costs of 
hospitalization ($4802 vs. $6873, p  .0001) mainly due to lower macrovascular 
complications ($1620 vs. $2661, p  0.001), and also lower ofﬁce visit costs ($3317 
vs. $4176, p  0.0001) and hospital outpatient visits ($5144 vs. $6608, p  0.0001) 
compared to glargine-treated patients. Although prescription costs of exenatide was 
higher than glargine ($1544 vs. $843, p  0.0001), exenatide-treated patients incurred 
signiﬁcantly lower costs of concomitant antidiabetic medications ($1283 vs. $1415, 
p  0.0001) and other prescription medications ($3235 vs. $3438, p  0.015) com-
pared to glargine-treated patients. CONCLUSIONS: Patients who initiated exenatide 
treatment had signiﬁcantly lower total medical costs mainly due to lower inpatient, 
outpatient and ER visits despite having higher total prescription costs. Although, the 
index-drug costs were higher for exenatide, cost savings were observed in hospitaliza-
tions, ofﬁce visits, and hospital outpatient visits.
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OBJECTIVES: To compare the use of opioids and health care costs between patients 
with diabetic peripheral neuropathic pain (DPNP) who initiated treatment with dulox-
etine versus other standard of care DPNP treatments. METHODS: This retrospective 
cohort study analyzed administrative claims database 2004–2006 from a large US 
commercially-insured population to assess opioid utilization and health care costs over 
